Drug manufacturer Merck is paying refunds for overcharges on 340B drugs purchased during the first two quarters of 2020.
Merck recently asked the U.S. Health Resources and Services Administration to post notices about its 340B ceiling price recalculations on the
…
Publisher’s Note: Since we first published this piece by Jennifer Lockwood of Ravin Consultants, there has been an important development that is addressed at the end of the story. We thank Jennifer and her team for alerting us and recommending that we
…
Companion bills in the Massachusetts House and Senate would restore the 340B program’s intent by stopping pharmacy benefit manager discrimination against any 340B covered entities and their contract pharmacies, the sponsor of the state Senate bill said during a recent
…
SPONSORED CONTENT
TIP: Double check your TPA’s 340B capture settings to ensure they match your manufacturer restriction designations.
If
Drug manufacturer Organon, the Merck spinoff with a focus on women’s health, today became the 22nd drug maker to impose conditions on 340B pricing involving delivery to contract pharmacies.
Covered entities began receiving an email from Organon around 3:00 p.m.
…
Drug manufacturer Novo Nordisk today announced that effective July 1 it will stop letting hospitals place bill to / ship to orders of 340B-purchased drugs to an unlimited number of contract pharmacies in exchange for related claims data.
It will,
…
The U.S. Centers for Medicare & Medicaid Services has sent its proposed remedy for almost five years of illegal Medicare Part B drug payments cuts for 340B hospitals to the White House for clearance to be published in the Federal
…
The U.S. Centers for Medicare & Medicaid Services wants to make Medicaid managed care organizations use Medicaid-specific codes and group numbers on beneficiary insurance cards to help states, MCOs, and 340B covered entities avoid invoicing manufacturers for prohibited duplicate 340B
…SPONSORED CONTENT
The 340B drug pricing program, which allows eligible healthcare providers known as covered entities to purchase medications at a reduced price, has been an incredibly valuable tool for providing affordable healthcare to underserved populations. However, the benefits of the 340B program
…
340B-eligible providers prescribe generic drugs at the same overall rate as non-340B providers, a study published in JAMA Health Forum found. “We found no evidence that 340B-eligible prescribers were systematically overprescribing brand-name drugs to generate revenue,” the authors said.
*Sign up for news summaries and alerts from 340B Report
